Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Film-forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film-forming polymer, an amine-rich adhesion promoter, and a volatile solvent. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing. In some cases, the film-forming gel composition can include lidocaine.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting settings for a treatment of a patient. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for providing a treatment to a patient based on a causal model that measures current causal relationships between input settings and effects of treatments on the patient; ii) receiving a measure of an effect of the treatment on the patient; and iii) adjusting, based on the measure of the effect of the treatment on the patient, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for optimizing a process of manufacturing a biologic pharmaceutical. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for manufacturing a batch of a biologic pharmaceutical based on a causal model that measures current causal relationships between input settings and a measure of a quality of batches of the biological pharmaceutical; ii) determining a measure of the quality of a batch of the biological pharmaceutical manufactured using the configuration of input settings; and iii) adjusting, based on the measure of the quality of the batch of the biological pharmaceutical, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for designing a clinical trial. In one aspect, the method comprises repeatedly performing the following: i) selecting, from a population of patients, patients for being treated with the treatment using a configuration of input settings, wherein the configuration is selected based on a causal model that measures current causal relationships between input settings and a measure of success of the clinical trial; ii) determining the measure of success of the clinical trial for which patients were selected using the certain configuration of input settings; and iii) adjusting, based on the measure of success of the clinical trial, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for controlling operations of one or more healthcare facilities. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for controlling operations of the healthcare facilities based on a causal model that measures current causal relationships between input settings and a measure of success of operations at the healthcare facilities; ii) receiving a measure of success of the operation of the healthcare facilities while controlled using the configuration of input settings; and iii) adjusting, based on the measure of success of the operation of the healthcare facilities while controlled using the configuration of input settings, the causal model.

Abstract: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific).

Abstract: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.

Abstract: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific).

Abstract: The disclosure provides methods for the treatment and prevention of periodontal disease. In preferred embodiments, the invention provides for local treatment of periodontal tissues with a pharmaceutical composition including an immune response modifier (IRM) selected from the group of immune response modifiers comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphtyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazopyridine amines.

Abstract: Methods for screening for compounds that selectively induce IFN-? production and methods for ameliorating conditions in a patient using a small molecule that selectively induces the production of IFN-? are disclosed.

Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compound affects at least one TLR-mediate cellular signaling pathway.

Abstract: The present invention provides methods for enhancing the immune responses induced by IRM compounds. Generally, the methods include administering a cytokine receptor agonist or a cytokine inducer prior to administering an IRM compound to a cell population.